Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France

Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year... Graefes Arch Clin Exp Ophthalmol (2017) 255:1651–1660 DOI 10.1007/s00417-017-3685-y MEDICAL OPHTHALMOLOGY Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France 1 2 3,4 5 Gérard Mimoun & Jean-Marc Ebran & Typhaine Grenet & Alain Donati & 4,6 7 Salomon-Yves Cohen & Anne Ponthieux Received: 21 April 2016 /Revised: 13 March 2017 /Accepted: 24 April 2017 /Published online: 10 May 2017 The Author(s) 2017. This article is an open access publication Abstract of eyes with VA gain of ≥15 letters was 3/19 (15.8%) and Purpose To evaluate the long-term effectiveness and safety of stable VA (change between −15 and +15 letters) was 10/19 ranibizumab 0.5 mg in patients with choroidal neovasculari- (52.6%). Mean (±SD) annual number of ranibizumab injec- zation (CNV) secondary to pseudoxanthoma elasticum (PXE) tions was 4.1 (±4.0), lower in the second versus first year. The in a real-world setting. most common reason for ranibizumab treatment was progres- Methods A descriptive, observational, multicenter study in a sion of neovascular activity (42.9%). No deaths or new safety retrospective and prospective cohort was conducted in France findings were reported. that included patients who had received at least one injection Conclusions In patients with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Graefe's Archive for Clinical and Experimental Ophthalmology Springer Journals

Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France

Loading next page...
 
/lp/springer_journal/ranibizumab-for-choroidal-neovascularization-secondary-to-q9pLMZ6DJ0
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Ophthalmology
ISSN
0721-832X
eISSN
1435-702X
D.O.I.
10.1007/s00417-017-3685-y
Publisher site
See Article on Publisher Site

Abstract

Graefes Arch Clin Exp Ophthalmol (2017) 255:1651–1660 DOI 10.1007/s00417-017-3685-y MEDICAL OPHTHALMOLOGY Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France 1 2 3,4 5 Gérard Mimoun & Jean-Marc Ebran & Typhaine Grenet & Alain Donati & 4,6 7 Salomon-Yves Cohen & Anne Ponthieux Received: 21 April 2016 /Revised: 13 March 2017 /Accepted: 24 April 2017 /Published online: 10 May 2017 The Author(s) 2017. This article is an open access publication Abstract of eyes with VA gain of ≥15 letters was 3/19 (15.8%) and Purpose To evaluate the long-term effectiveness and safety of stable VA (change between −15 and +15 letters) was 10/19 ranibizumab 0.5 mg in patients with choroidal neovasculari- (52.6%). Mean (±SD) annual number of ranibizumab injec- zation (CNV) secondary to pseudoxanthoma elasticum (PXE) tions was 4.1 (±4.0), lower in the second versus first year. The in a real-world setting. most common reason for ranibizumab treatment was progres- Methods A descriptive, observational, multicenter study in a sion of neovascular activity (42.9%). No deaths or new safety retrospective and prospective cohort was conducted in France findings were reported. that included patients who had received at least one injection Conclusions In patients with

Journal

Graefe's Archive for Clinical and Experimental OphthalmologySpringer Journals

Published: May 10, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off